"instanceType","rationale","uuid:ID","versionIdentifier","id"
"StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","035aaa31-4cca-4da2-9c0b-3cf2cf1d16c8","2","StudyVersion_1"
